Clinical Trial

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Study acronym: AGLOW
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-07-31
notable Trial sites expanded: 35 -> 38 locations 2026-04-08
Trial Details
NCT Number NCT07161037
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Enrollment 26 participants
Start Date 2025-11-19
Primary Completion 2027-07-22 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-11